echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China Resources Shuanghe Clindamycin Phosphate Injection Passes Consistency Evaluation of Generic Drugs

    China Resources Shuanghe Clindamycin Phosphate Injection Passes Consistency Evaluation of Generic Drugs

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 16, China Resources Shuanghe announced that its wholly-owned subsidiary Shuanghe Limin had received the “Approval Notice for Supplementary Drug Application” (Notice No.


    Clindamycin phosphate is a derivative of clindamycin, which has no antibacterial activity in vitro.


    Shuanghe Limin started the consistency evaluation of the drug in 2019, submitted the application for consistency evaluation to the State Food and Drug Administration on December 29, 2020, and received the acceptance notice on January 6, 2021.


    As of the date of this announcement, the cumulative R&D investment of Shuanghe Limin on the consistency evaluation of the drug was RMB 6,006,700 (unaudited)


    Clindamycin Phosphate Injection was developed by Pharmacia and Upjohn Co (a subsidiary of Pfizer) under the trade name Cleocin Phosphate and was approved in the United States in 1972


    The sales revenue of Shuanghe Limin in 2020 is 41.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.